542 related articles for article (PubMed ID: 1317462)
21. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease.
Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU
Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
[TBL] [Abstract][Full Text] [Related]
24. [Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course].
Reles A; Press MF; Schönborn I; Lichtenegger W; Strohmeyer T
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():93-7. PubMed ID: 8672936
[TBL] [Abstract][Full Text] [Related]
25. Relationship among p53, stage, and prognosis of large bowel cancer.
Nathanson SD; Linden MD; Tender P; Zarbo RJ; Jacobsen G; Nelson LT
Dis Colon Rectum; 1994 Jun; 37(6):527-34. PubMed ID: 8200229
[TBL] [Abstract][Full Text] [Related]
26. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
27. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J
Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432
[TBL] [Abstract][Full Text] [Related]
29. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of p53 protein expression in breast carcinomas.
Hurlimann J
Pathol Res Pract; 1993 Nov; 189(9):996-1003. PubMed ID: 8302733
[TBL] [Abstract][Full Text] [Related]
32. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
33. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
34. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
35. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
37. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive factors of invasive ductal breast carcinomas.
Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
Tsuda H; Iwaya K; Fukutomi T; Hirohashi S
Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903
[TBL] [Abstract][Full Text] [Related]
40. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.
Jacobs TW; Prioleau JE; Stillman IE; Schnitt SJ
J Natl Cancer Inst; 1996 Aug; 88(15):1054-9. PubMed ID: 8683636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
